Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gastrointestinal 1

Conditions

Melanoma 11Breast Neoplasms 3Triple Negative Breast Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Carcinoma, Merkel Cell 2Squamous Cell Carcinoma of Head and Neck 1Peritoneal Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1Carcinoma, Basal Cell 1Advanced Non CNS Tumors 1Adenocarcinoma 1

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × talimogene laherparepvec × Clear all
NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT03256344 2024-05-14

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Amgen

Phase 1 Completed
36 enrolled 16 charts
BreastGastrointestinal

Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡